Se­bas­t­ian Guth sharp­ens his fo­cus at Bay­er; As CD47 strug­gles per­sist, I-Mab ap­points CEO

→ Bay­er is re­fin­ing Se­bas­t­ian Guth’s role on June 30, nam­ing him se­nior Bay­er rep­re­sen­ta­tive and pres­i­dent of Bay­er US. Guth had led phar­ma­ceu­ti­cals op­er­a­tions in the Amer­i­c­as since De­cem­ber 2018, and he’ll still be in charge of the phar­ma­ceu­ti­cals busi­ness for the US and Cana­da, as EMEA com­mer­cial op­er­a­tions leader Heike Prinz han­dles the Latin Amer­i­ca phar­ma­ceu­ti­cals busi­ness. Guth is a 17-year vet­er­an with Bay­er who has al­so been pres­i­dent and CEO of the Ger­man multi­na­tion­al’s health­care group in Japan. The moves come as for­mer Roche Phar­ma­ceu­ti­cals chief Bill An­der­son is about to com­plete his first month as CEO. In Wern­er Bau­mann’s fi­nal days, Bay­er trimmed its pipeline and al­so struck a ra­dio­ther­a­py deal with Bi­cy­cle Ther­a­peu­tics worth $45 mil­lion up­front.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER